Dendreon chief to step down for personal reasons
US biotech firm Dendreon (Nasdaq: DNDN) revealed last evening that John Johnson plans to step down as president and chief executive officer for personal reasons.
Mr Johnson has resigned from the board, effective June 3, 2014, and the board has elected Douglas Watson, Dendreon’s lead independent director, as chairman. Mr Watson has served as one of Dendreon’s independent directors since February 2000. He is chief executive officer of Pittencrieff Glen Associates, a consulting firm that he founded in 1999. Prior to that, Mr Watson’s career spanned 33 years with Geigy/Ciba-Geigy/Novartis, during which time he held a variety of positions.
Dendreon’s board is working with an executive search firm to help identify Mr Johnson’s successor. Mr Johnson will serve as chief executive officer until August 15, 2014.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze